IMV Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 apr 2023 @ 21:58):

Stats
Dagens volum	44 894.00
Gjennomsnittsvolum	152 414
Markedsverdi	9.63M
EPS	$0 ( 2024-03-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.181
ATR14	$0.0680 (56.62%)

Volum Korrelasjon

Lang: 0.02 (neutral)

Kort: 0.97 (very strong)

Signal:(34.598) Expect same movement, but be aware

IMV Inc Korrelasjon

10 Mest positive korrelasjoner
NAKD	0.952
MDXH	0.943
GSMG	0.941
SIRI	0.94
AHPI	0.939
TENX	0.938
TSHA	0.937
CSSE	0.936
BCBP	0.933
SINT	0.933

10 Mest negative korrelasjoner
KIN	-0.957
ATCX	-0.957
ALGM	-0.955
SRRA	-0.948
NCAC	-0.945
OBT	-0.942
INTA	-0.939
GXII	-0.939
ITI	-0.938
DHCAU	-0.937

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

IMV Inc Korrelasjon - Valuta/Råvare

-0.65
( weak negative )

-0.82
( strong negative )

0.59
( weak )

-0.64
( weak negative )

0.27
( neutral )

IMV Inc Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-4.61

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-4.61

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0737

FY	2020
Omsetning:	$3 000.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0578

Financial Reports:

No articles found.

IMV Inc

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.